Rankings
▼
Calendar
XERS
Xeris Biopharma Holdings, Inc.
$982M
Q4 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$2M
+132.7% YoY
Gross Profit
$261,000
14.0% margin
Operating Income
-$33M
-1759.7% margin
Net Income
-$33M
-1774.8% margin
EPS (Diluted)
$-1.23
QoQ Revenue Growth
+477.1%
Cash Flow
Operating Cash Flow
-$30M
Free Cash Flow
-$30M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$109M
Total Liabilities
$95M
Stockholders' Equity
$14M
Cash & Equivalents
$20M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$2M
$801,000
+132.7%
Gross Profit
$261,000
$759,000
-65.6%
Operating Income
-$33M
-$20M
-61.5%
Net Income
-$33M
-$20M
-62.0%
← FY 2019
All Quarters
Q1 2020 →
XERS Q4 2019 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena